Birth Defects Associated With Exposure to Lamotrigine in Pregnancy (EUROCAT)
Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Epilepsy
Intervention: Lamotrigine monotherapy (Drug); No anti-epileptic drug exposure (Drug); Non lamotrigine anti-epileptic drug monotherapy (Drug)
Phase: N/A
Status: Completed
Sponsored by: GlaxoSmithKline Official(s) and/or principal investigator(s): GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline
Summary
In 2007 a case control study was completed within the EUROCAT European network of congenital
anomaly registers to test the hypothesis that first trimester lamotrigine monotherapy
exposure is associated with an increased risk of isolated oral clefts. This study found no
statistically significant increased risk of oral clefts compared with other defects
following lamotrigine exposure in the uterus. The EUROCAT Antiepileptic Drug (AED)
Database, established for the original case control study in 2007, will now be expanded to
include an additional five to six years worth of data. These data will provide greater
power to investigate the risk of isolated oral clefts, specific cleft types and potential
associations with additional specific malformation types (e. g. neural tube defects). Data
on cases of isolated oral clefts registered between 1993 and 2012 will be extracted from
EUROCAT member registers meeting set inclusion criteria (ensuring completeness of outcome
and exposure data). The primary comparison group will include all non oral cleft, non
chromosomal malformations as the registers do not collect data on non malformed infants.
This study will also be powered to include a second control group of chromosomal
malformations, very unlikely to be associated with medication exposure. Data on exposure to
anti-epileptic drugs (AEDs) during the first trimester of pregnancy will be extracted along
with other key covariates including age of mother, history of epilepsy and gestational age
of the infant. Primary analyses, using logistic regression, will compare the lamotrigine
monotherapy versus no AED use across case and control groups and a secondary analysis will
compare lamotrigine monotherapy versus other AED monotherapy (with and without valproate).
Data will also be monitored for patterns of lamotrigine exposure across additional specific
malformation groups of interest.
Clinical Details
Official title: Monitoring of Specific Birth Defects Associated With Exposure to Lamotrigine in Pregnancy Through the EUROCAT Network
Study design: Observational Model: Case Control, Time Perspective: Retrospective
Primary outcome: Non chromosomal, non monogenic, isolated oral clefts
Secondary outcome: Non oral cleft, non chromosomal malformationsAll chromosomal malformations
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Individual population-based registers within EUROCAT are eligible to participate if:
- Anti-epileptic drug exposure is recorded for at least 3 per 1000 malformed
infants/fetuses (figures below this threshold indicate potential under reporting of
medication exposure).
- Specific drug names or complete 7 digit Anatomical Therapeutic Chemical (ATC)
classification codes are available for at least 80% of AED exposed infants/fetuses.
Exclusion Criteria:
- As above
Locations and Contacts
Additional Information
Starting date: May 2009
Last updated: September 29, 2014
|